Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc CRDL


Primary Symbol: T.CRDL Alternate Symbol(s):  T.CRDL.W.A

Healthcare
Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.


TSX:CRDL - Post by User

Cardiol Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(79)
•••
Post by Youhillmanon Apr 14, 2022 4:03pm
358 Views
Post# 34605057

Today in the Financial News…

Today in the Financial News…

Nice run today....this was published today in the Financial News...maybe part of the reason.

I've sold off most of what I owned in the $4-5 profit range as I've been disappointed with Cardiol's follow through on some of their previous stated business opportunities but hold enough to still make some serious coin if this thing flies....

https://www.the-financialnews.com/heres-how-investors-can-make-2000-with-this-stock/?gclid=Cj0KCQjwjN-SBhCkARIsACsrBz5Io-zkGBtDMrZ4WcEncUdkYsIJIxgXe-9yNl0iCO957iYfny-2MBYaAvj3EALw_wcB

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities